Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,467.00GBp
2 Dec 2016
Change (% chg)

-1.50p (-0.10%)
Prev Close
1,468.50p
Open
1,462.00p
Day's High
1,471.50p
Day's Low
1,452.00p
Volume
6,542,323
Avg. Vol
9,198,998
52-wk High
1,745.56p
52-wk Low
1,259.32p

Select another date:

Fri, Nov 25 2016

BRIEF-GlaxoSmithKline submits marketing application for shingles vaccine to EMA

* GSK announces EU regulatory submission of candidate vaccine for prevention of shingles

GSK chases Astra with start of big anemia drug trials

LONDON GlaxoSmithKline has started pivotal trials of an experimental anemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude.

GSK chases Astra with start of big anaemia drug trials

LONDON, Nov 24 GlaxoSmithKline has started pivotal trials of an experimental anaemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude.

BRIEF-GSK's Mepolizumab meets endpoints in phase 3 EGPA study

* Phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis

BRIEF-GSK receives FDA approval for expanded indication for flulaval quadrivalent (influenza vaccine) for infants 6 months and older

* GSK receives FDA approval for expanded indication for flulaval quadrivalent (influenza vaccine) for infants 6 months and older Source text for Eikon: Further company coverage:

BRIEF-GSK files regulatory submission of candidate vaccine

* GSK files regulatory submission of candidate vaccine for prevention of shingles in Canada

GlaxoSmithKline seeks U.S. approval for triple lung drug

LONDON GlaxoSmithKline said on Monday it had filed its new three-in-one inhaled lung drug for U.S. approval, putting it on track to reach the market ahead of rivals in 2017, assuming it wins a green light.

GlaxoSmithKline seeks U.S. approval for triple lung drug

LONDON, Nov 21 GlaxoSmithKline said on Monday it had filed its new three-in-one inhaled lung drug for U.S. approval, putting it on track to reach the market ahead of rivals in 2017, assuming it wins a green light.

BRIEF-GSK files regulatory submission in U.S. for COPD treatment

* Files regulatory submission in US for once-daily closed triple combination therapy ff/umec/vi for patients with copd

Ex-sleuths sue GlaxoSmithKline over imprisonment in China

Two former corporate investigators have sued GlaxoSmithKline, alleging the drugmaker misled them and induced them to investigate an innocent person, resulting in their imprisonment.

Select another date: